Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Description

International retrospective observational cohort study aimed to describe a molecular classification for NMZL.

Conditions

Nodal Marginal Zone Lymphoma

Talk to us

Study Overview

On this page

Study Details

Study overview

International retrospective observational cohort study aimed to describe a molecular classification for NMZL.

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Condition
Nodal Marginal Zone Lymphoma
Intervention / Treatment

-

Contacts and Locations

Miami

University of Miami, Miami, Florida, United States, 33136

New York

Weill Cornell Medical, New York, New York, United States, 10065

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Male or female adults 18 years or older
  • 2. Diagnosis of NMZL on lymph node histology after Jan 1st, 2000
  • 3. Availability of tumor material from lymph node (either frozen or FFPE) collected when the patient was treatment naïve
  • 4. Availability of the baseline and follow-up annotations
  • 1. Nodal spread of a clinically occult extranodal MZL (this must have been ruled out by carefully evaluating the extranodal tissues draining to the involved lymph nodes by imaging or endoscopy)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

International Extranodal Lymphoma Study Group (IELSG),

Davide Rossi, MD, STUDY_CHAIR, Oncology Institute of Southern Switzerland and Institute of Oncology Research

Study Record Dates

2026-12-31